LifeSci Capital Initiates Coverage of Heron Therapeutics

Developing Enhanced Versions of Approved Products Using the Proprietary Biochronomer™ Polymer-Based Drug Delivery Technology

Report Available Here: http://www.lifescicapital.com/equity-research/heron/

NEW YORK, NY / ACCESSWIRE / February 7, 2017 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Heron Therapeutics (NasdaqCM: HRTX), a specialty pharmaceutical company developing enhanced versions of approved treatments using its proprietary Biochronomer™ polymer-based drug delivery technology. The Company’s approved product, Sustol, is a long-acting version of granisetron, a 5-HT3 receptor antagonist used for the prevention of chemotherapy induced nausea and vomiting (CINV).

Sustol was approved in August 2016 for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Notably, this is the only extended release 5-HT3 receptor antagonist approved for a 5-day CINV prevention in MEC and AC based regimens. Heron launched Sustol in October 2016.

Lead clinical candidate Cinvanti is an intravenous formulation of aprepitant, an approved P/neurokinin-1 (NK-1) receptor antagonist for the prevention of acute and delayed CINV caused by MEC and HEC. NK-1 antagonists are used in combination with 5-HT3 antagonists. Cinvanti was designed to offer a more tolerable profile than IV Emend by excluding polysorbate 80 from the formulation. This excipient is associated with adverse events such as injection site reactions and hypersensitivity reactions. Positive results from a Phase Ib bioequivalency study reported in February 2016 showed that Cinvanti has an improved safety profile over Emend. Heron is developing this asset under a 505(b)(2) registration pathway. The Company submitted an NDA in January of 2017.

In a 58 page Initiation Report, LifeSci Capital explains the clinical data supporting Sustol and Cinvanti. We outline the market opportunity for each indication and discuss the landscape of approved agents and those in development.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on OncoSec Medical as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 454579